GO
Loading...

GlaxoSmithKline PLC

More

  • MONROVIA, Feb 2- Liberia began a trial of experimental Ebola vaccines on Monday, involving thousands of volunteers as part of an effort to slow the spread of the deadly haemorrhagic fever and prevent future outbreaks. The epidemic has killed more than 8,900 people in West Africa since it began more than a year ago, overwhelming weak healthcare systems in Guinea,...

  • MONROVIA, Feb 2- Liberia began a trial of experimental Ebola vaccines on Monday, involving thousands of volunteers as part of an effort to slow the spread of the deadly haemorrhagic fever and prevent future outbreaks. The epidemic has killed more than 8,800 people in West Africa since it began more than a year ago, overwhelming weak healthcare systems in Guinea,...

  • LONDON, Feb 1- As West Africa's devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast. Determined not to lose scientific momentum that could make the world's first effective Ebola interventions a reality, researchers...

  • NEW YORK, Jan 29- When Marty Weinstein decided to quit smoking, he took a friend's advice and tried electronic cigarettes rather than government-approved nicotine replacement products. E-cigarette makers in the United States are barred from explicitly marketing the products as smoking cessation devices, but have found ways to appeal legally to smokers who...

  • BERLIN, Jan 27- International donors pledged $7.5 billion on Tuesday to immunize 300 million children in poor countries against deadly diseases such as diarrhea and pneumonia. At a Global Alliance for Vaccines and Immunization conference in Berlin, Microsoft founder Bill Gates and the British government topped the donations list at $1.55 billion and $1.5...

  • Novartis flags faster sales, profit growth for 2015 Tuesday, 27 Jan 2015 | 2:48 AM ET
    Joe Jimenez, CEO of Novartis, at 2015 WEF in Davos, Switzerland.

    Novartis forecast sales and profits to grow at a faster pace this year driven by recent drug successes and its portfolio overhaul.

  • *Core EPS $1.21 vs $1.18 forecast in Reuters poll. ZURICH, Jan 27- Swiss drugmaker Novartis forecast sales and profits to grow at a faster pace this year as recent drug successes and its portfolio overhaul help it weather the impact of generic competition. Novartis unveiled a transformative series of deals last year which will see it focus on a smaller number of...

  • LONDON, Jan 26- Pfizer is to cut the price of its pneumococcal vaccine Prevenar 13 by 6 percent to $3.10 per dose in poor countries as part of a commitment to the GAVI global vaccines alliance, the U.S. drugmaker said on Monday. Pfizer's move comes as GAVI holds a major funding conference in Berlin at which it hopes to raise $7.5 billion from donors to pay for increased...

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been dispatched to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The World Health Organization said on Thursday the Ebola outbreak in West Africa, the worst in history, appears to be waning but cautioned against complacency.

  • *Disease outbreaks high on Davos agenda after Ebola. DAVOS, Switzerland, Jan 23- The worst-ever Ebola epidemic is waning, but after ravaging three West African nations and spreading fear from Dallas to Madrid, it has hammered home the message that the world needs a better detective system for emerging diseases. Risks posed by pandemic threats such as deadly...

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been shipped to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The vaccine, co-developed by the National Institutes of Health in the United States and Okairos, a biotechnology firm acquired by GSK in 2013, is currently being tested...

  • Ebola vaccine trials to begin in Liberia Thursday, 22 Jan 2015 | 3:45 PM ET
    Health workers don protective equipment at the Island Clinic in Monrovia, Liberia.

    A clinical trial of two experimental Ebola vaccines is expected to start in Liberia in the next couple of weeks, the NIH said.

  • DAVOS, Switzerland, Jan 22- The GAVI global vaccines alliance is seeking to raise $7.5 billion at a funding conference in Berlin next week, as its battle to prevent infectious diseases in millions of children reaches an expected peak. The economic benefits of that will be some $80 billion and $100 billion, underscoring the cost-effectiveness of vaccines as a...

  • INSIGHT-The smoke around e-cig science Thursday, 22 Jan 2015 | 6:00 AM ET

    *Wide variety of e-cigs a problem for researchers. *Tobacco firms join e-cig companies in sponsoring research. LONDON, Jan 22- From Apple Pie to Bubbly Bubble Gum, Irish Car Bomb or Martian bar- from Mars!

  • DAVOS, Switzerland, Jan 21- Takeda Pharmaceutical, Japan's largest drugmaker, is ready to look at doing deals now that it has refocused operations, its incoming chief executive said on Wednesday. "We don't want to be passive and we don't want to watch the train passing," he told Reuters on the fringes of the World Economic Forum in Davos. As COO, Weber has overseen a...

  • Vaccinating children becoming unaffordable: Report Tuesday, 20 Jan 2015 | 2:22 PM ET
    A child receives a vaccine in a makeshift field clinic of the Doctors Without Borders (MSF) organisation during a vaccination program against measles in Bangui, Central African Republic.

    The cost of a vaccination program is 68 times more expensive than is was in 2001. Doctors Without Borders wants companies to slash prices.

  • LONDON, Jan 20- the international charity Medecins Sans Frontieres urged drugmakers GlaxoSmithKline and Pfizer on Tuesday to slash the price of their pneumococcal vaccines to $5 per child in poor countries. Pfizer also said its pneumococcal shot, Prevenar 13, was highly complex. It said GSK and Pfizer had together reported more than $19 billion in global...

  • J&J Ebola vaccine gets $115M to speed development Friday, 16 Jan 2015 | 8:57 AM ET
    A worker in vaccine production at drugmaker GlaxoSmithKline in Saint-Amand-les-Eaux, France.

    Johnson & Johnson said that newly formed groups supporting work on its experimental Ebola vaccine would receive $115 million to speed development.

  • LONDON, Jan 16- Johnson& Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros from Europe's Innovative Medicines Initiative to speed development. The new initiative will see J&J join with institutions including the London School of Hygiene& Tropical Medicine, the University of...

  • LONDON, Jan 16- GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said. In an interview with Reuters, Andrew Witty also said he and his team had spent "a few days" exploring whether the drugmaker...